Graves' hyperthyroidism-related pancytopenia: a case report with literature review.
Graves’ disease
Pancytopenia
Review
Journal
Hormones (Athens, Greece)
ISSN: 2520-8721
Titre abrégé: Hormones (Athens)
Pays: Switzerland
ID NLM: 101142469
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
22
05
2020
accepted:
28
06
2020
pubmed:
9
7
2020
medline:
29
10
2021
entrez:
9
7
2020
Statut:
ppublish
Résumé
Occurrence of pancytopenia in patients with untreated hyperthyroidism is extremely rare. To the best of our knowledge, only 30 cases have been reported in the English literature. Accurate diagnosis and appropriate tailored therapy are challenging due to the variegated causes of pancytopenia and the potential hematological toxicity of antithyroid drugs (ATDs). We present a 51-year-old Caucasian man with newly diagnosed Graves' disease showing pancytopenia and liver dysfunction. Although in this context the use of ATDs is still under debate, low-dose methimazole therapy was able to induce resolution of both pancytopenia and liver dysfunction, along with euthyroidism restoration. Searching in the English literature for previous studies, we identified only 30 cases worldwide to form our database. A demographic as well as clinical, laboratory, and histopathological analysis was performed. In most cases, the recovery of biochemical euthyroidism through the use of ATDs induced the resolution of pancytopenia (at laboratory and histological levels). Our review provides clinical, laboratory, and histopathological features of Graves's hyperthyroidism-related pancytopenia with a view to improving the knowledge of this rare hematological complication and assisting in the decision-making process regarding therapeutic options.
Identifiants
pubmed: 32638234
doi: 10.1007/s42000-020-00227-5
pii: 10.1007/s42000-020-00227-5
doi:
Substances chimiques
Antithyroid Agents
0
Methimazole
554Z48XN5E
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
93-100Références
Burch HB (2013) Overview of the clinical manifestations of thyrotoxicosis. In: Braverman LE (ed) Werner & Ingbar’s The Thyroid, 10th edn. LippincottWilliams &Wilkins, Philadelphia, pp 434–440
Aggarwal A, Tee SA, Saqib W, Fretwell T, Summerfield GP, Razvi S (2017) Treatment of hyperthyroidism with antithyroid drugs corrects mild neutropenia in Graves’ disease. Clin Endocrinol (Oxf) 85(6):949–953
doi: 10.1111/cen.13133
Lin TY, Shekar AO, Li N, Yeh MW et al (2017) Incidence of abnormal liver biochemical tests in hyperthyroidism. Clin Endocrinol (Oxf) 86(5):755–759
doi: 10.1111/cen.13312
Ross DS, Burch HB, Cooper DS, Greenlee MC et al (2016) 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26:1343–1421
pubmed: 27521067
doi: 10.1089/thy.2016.0229
Jameson JL, Kasper DL, Longo DL (Dan Louis) 1949-, Fauci AS 1940-, Hauser SL, Loscalzo J (2018) Harrison’s principles of internal medicine. 20th edn. New York: McGraw-Hill Education
Nakamura S, Isaji M, Ishimori M (2001) Morning granulocytopenia in a case of Graves’ disease. Endocr J 48:181–184
pubmed: 11456265
doi: 10.1507/endocrj.48.181
Hertz S, Lerman J (1932) The blood picture in exophthalmic goitre and its changes resulting from iodine and operation: a study by means of the supravital technique. J Clin Invest 11:1179–1196
pubmed: 16694096
pmcid: 435873
doi: 10.1172/JCI100471
Lima CS, Wittmann DE, Catro V, Tambascia et al (2006) Pancytopenia in untreated patients with Graves’ disease. Thyroid 16:403–409
pubmed: 16646688
doi: 10.1089/thy.2006.16.403
Soeki T, Tamura Y, Kondo N et al (2001) A case of thyrotoxicosis with pancytopenia. Endocr J 48(3):385–389
pubmed: 11523911
doi: 10.1507/endocrj.48.385
Shaw B, Mehta AB (2002) Pancytopenia responding to treatment of hyperthyroidism: a clinical case and review of the literature. Clin Lab Haematol 24(6):385–387
pubmed: 12452820
doi: 10.1046/j.1365-2257.2002.00460.x
Killick SB, Bown N, Cavenagh J et al (2016) British Society for Standards in Haematology. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 172(2):187–207
pubmed: 26568159
doi: 10.1111/bjh.13853
Young NS (2018) Aplastic anemia. N Engl J Med 379(17):1643–1656
pubmed: 30354958
pmcid: 6467577
doi: 10.1056/NEJMra1413485
Watanabe N, Narimatsu H, Noh JY et al (2012) Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves’ disease. J Clin Endocrinol Metab 97(1):E49–E53
pubmed: 22049174
doi: 10.1210/jc.2011-2221
Talansky AL, Schulman P, Vinciguerra VP, Margouleff D, Budman DR, Degnan TJ (1981) Pancytopenia complicating Graves’ disease and drug-induced hypothyroidism. Arch Intern Med 141(4):544–545
pubmed: 6894229
doi: 10.1001/archinte.1981.00340040140037
Ladwig P, Coles R, Fischer E, Spurrett B (1995) Thyrotoxicosis in pregnancy presenting as pancytopenia. Aust N Z J Obstet Gynaecol 35(4):457–460
pubmed: 8717580
doi: 10.1111/j.1479-828X.1995.tb02168.x
Bertola G, Bocchia M, Ribotto P, Orlandini B, Torchio G (1998) Hematological changes in hyperthyroidism. A case report. Recenti Prog Med 89(4):180–182
pubmed: 9612010
Akoum R, Michel S, Wafic T et al (2007) Myelodysplastic syndrome and pancytopenia responding to treatment of hyperthyroidism: peripheral blood and bone marrow analysis before and after antihormonal treatment. J Cancer Res Ther 3(1):43–46
pubmed: 17998720
doi: 10.4103/0973-1482.31972
Das PK, Wherrett D, Dror Y (2007) Remission of aplastic anemia induced by treatment for Graves disease in a pediatric patient. Pediatr Blood Cancer 49(2):210–212
pubmed: 16456859
doi: 10.1002/pbc.20640
Aydin Y, Berker D, Ustün I et al (2008) A very rare cause of aplastic anemia: Graves disease. South Med J 101(6):666–667
pubmed: 18528229
doi: 10.1097/SMJ.0b013e318172fcb8
Hegazi M, Kumar R, Bitar Z, Ibrahim E (2008) Pancytopenia related to Graves’ disease. Ann Saudi Med 28(1):48–49
pubmed: 18299644
pmcid: 6074226
Low B-H, Victor Kok VC-K (2009) Hyperthyroidism with pancytopenia: a case report and literature review. Formos J Endocrin Metab 1(1):23–28
Chen YH, Lin HJ, Chen KT (2009) Rare presentations of hyperthyroidism—Basedow’s paraplegia and pancytopenia. Am J Emerg Med 27(2):258.e1-2
pubmed: 19371562
Raina S, Kaul R, Mruthyunjaya M (2012) Pancytopenia with cellular bone marrow related to Graves’ hyperthyroidism. Indian J Endocrinol Metab 16(3):478–479
pubmed: 22629533
pmcid: 3354874
doi: 10.4103/2230-8210.95739
Loh HH, Tan F (2013) Pancytopenia in a patient with Grave’s disease. Med J Malaysia 68(4):372–373
pubmed: 24145274
Naji P, Kumar G, Dewani S, Diedrich WA, Gupta A (2013) Graves’ disease causing pancytopenia and autoimmune hemolytic anemia at different time intervals: a case report and a review of the literature. Case Rep Med 2013:194542
pubmed: 24319463
pmcid: 3844236
doi: 10.1155/2013/194542
Garcia J, Ld F, Ellinger V, Wolff M (2014) Marrow hypoplasia: a rare complication of untreated Grave’s disease. Arq Bras Endocrinol Metabol 58(9):953–957
pubmed: 25627052
doi: 10.1590/0004-2730000003216
Garla VV, Abdul Salim S, Yanes-Cardozo LL (2018) Pancytopenia: a rare complication of Graves’ disease. BMJ Case Rep 9
Pincet L, Gorostidi F (2018) Graves disease causing pancytopenia: case report and literature review. Clin Med Insights Case Rep 11:1179547618781090
pubmed: 30083058
pmcid: 6069025
doi: 10.1177/1179547618781090
Li JC, Nandiraju D, Jabbour S, Kubey AA (2019) Pancytopenia and lymphoid organ hyperplasia in a patient with Graves disease: response to antithyroid drug therapy. AACE Clin Case Rep 5(6):E388–E392
pubmed: 31967078
pmcid: 6873849
doi: 10.4158/ACCR-2019-0170
Hamid OA, Fadul AM, Batia TB, Yassin MA (2020) Graves’ disease-related pancytopenia improved after radioactive iodine ablation. Case Rep Oncol 13(1):295–298
pubmed: 32308594
pmcid: 7154234
doi: 10.1159/000506440
Rafhati AN, See CK, Hoo FK, Badrulnizam LB (2014) A report of three cases of untreated Graves’ disease associated with pancytopenia in Malaysia. Electron Physician 6(3):877–882
pubmed: 25763162
pmcid: 4324290
Hinterberger-Fischer M, Kier P, Forstinger I et al (1994) Coincidence of severe aplastic anaemia with multiple sclerosis or thyroid disorders. Report of 5 cases. Acta Haematol 92(3):136–139
pubmed: 7871951
doi: 10.1159/000204203
Kebapcilar L, Yeşil S, Bayraktar F et al (2005) Recovery from pancytopaenia and liver dysfunction after administration of propylthiouracil for Graves’ disease. N Z Med J 118(1220):U1615
pubmed: 16132076
Behera KK, Agrawal K, Adhya AK (2019) Graves’ disease with pancytopenia and hepatic dysfunction: a rare case presentation. Indian J Nucl Med 34(1):38–41
pubmed: 30713378
pmcid: 6352650
doi: 10.4103/ijnm.IJNM_134_18
Baagar KA, Siddique MA, Arroub SA, Ebrahim AH, Jayyousi AA (2017) Atypical complications of Graves’ disease: a case report and literature review. Case Rep Endocrinol 2017:6087135
pubmed: 28348902
pmcid: 5350306
Ford HC, Carter JM (1988) The haematology of hyperthyroidism: abnormalities of erythrocytes, leucocytes, thrombocytes and haemostasis. Postgrad Med J 64:735–742
pubmed: 3076660
pmcid: 2429012
doi: 10.1136/pgmj.64.756.735
Kawa MP, Grymula K, Paczkowska E et al (2010) Clinical relevance of thyroid dysfunction in human haematopoiesis: biochemical and molecular studies. Eur J Endocrinol 162(2):295–305
pubmed: 19903799
doi: 10.1530/EJE-09-0875
Gao Y, Shen HJ, Zhou P et al (2014) Relationship between leukopenia and intercellular adhesion molecules in Graves’ disease. West Indian Med J 63(6):601–604
pubmed: 25803374
Panzer S, Haubenstock A, Minar E (1990) Platelets in hyperthyroidism: studies on platelet counts, mean platelet volume, 111-indium-labeled platelet kinetics, and platelet-associated immunoglobulins G and M. J Clin Endocrinol Metab 70:491–496
pubmed: 2298861
doi: 10.1210/jcem-70-2-491
Cheung E, Liebman HA (2009) Thyroid disease in patients with immune thrombocytopenia. Hematol Oncol Clin North Am 23(6):1251–1260
pubmed: 19932432
doi: 10.1016/j.hoc.2009.08.003
Weitzman SA, Stossel TP, Harmon DC, Daniels G, Maloof F, Ridgway EC (1985) Antineutrophil autoantibodies in Graves’ disease: implications of thyrotropin binding to neutrophils. J Clin Invest 75:119–123
pubmed: 3838096
pmcid: 423416
doi: 10.1172/JCI111663
Volpé R (2001) The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte immunocyte signalling: a review. Curr Pharm Des 7(6):451–460
pubmed: 11281852
doi: 10.2174/1381612013397898
Huang MJ (1995) Liaw YF (1995) Clinical associations between thyroid and liver diseases. J Gastroenterol Hepatol 10:344–350
pubmed: 7548816
doi: 10.1111/j.1440-1746.1995.tb01106.x
Vasileiou M, Gilbert J, Fishburn S, Boelaert K, Guideline Committee (2020) Thyroid disease assessment and management: summary of NICE guidance. BMJ 368:m41
pubmed: 31996347
doi: 10.1136/bmj.m41
Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH (2018) 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J 7(4):167–186
pubmed: 30283735
pmcid: 6140607
doi: 10.1159/000490384